4basebio (4BB) has released its full-year results for the period ended 31 December 2024, reporting an 84% YoY increase in revenue to £0.93m, up from £0.51m. This growth reflects the group's accelerated strategy to establish itself as a key supplier of GMP-grade synthetic DNA for clinical applications. While reported revenues were below our 2024 estimate of £1.5m, we continue to view revenue as a secondary performance indicator for 4BB at this stage. The business remains in the early phases of de ....
